Development Pipeline

Development Pipeline

Poziotinib

  • EGFR or HER2 Exon 20 Insertion Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Phase 1 Phase 2 Phase 3 Approved
  • HER2-Positive Metastatic Breast Cancer
    Phase 1 Phase 2 Phase 3 Approved
  • HER2-Positive Advanced or Metastatic Breast Cancer in Combination With T-DM1
    Phase 1 Phase 2 Phase 3 Approved
For more information click here.

ROLONTIS® (eflapegrastim)

  • Chemotherapy-Induced Neutropenia (ADVANCE)
    Phase 1 Phase 2 Phase 3 Approved
  • Chemotherapy-Induced Neutropenia (RECOVER)
    Phase 1 Phase 2 Phase 3 Approved
For more information click here.

Apaziquone

  • Non-Muscle Invasive Bladder Cancer (CONQUER)
    Phase 1 Phase 2 Phase 3 Approved
For more information click here.
Developmental Trial Pivotal Trial